A stethoscope resting on medical documents in a clinical setting.
Health

Hyderabad Doctor Secures Affordable Treatment for Rare Genetic Disorder

Illustration: NexVani Media

By: NexVani DeskDate: 21 November 2026Views: 0

A Hyderabad-based pediatrician has successfully reduced the annual cost of a life-saving medication for seven children suffering from a rare genetic syndrome.

A Hyderabad-based pediatrician, Dr. Sivaranjani Santosh, has successfully orchestrated a cross-border humanitarian effort to secure affordable medication for seven Indian children diagnosed with Allanโ€“Herndonโ€“Dudley syndrome (AHDS). While many people often search for how Hyderabad developed into a medical hub, this case highlights a critical breakthrough in accessing treatment for a rare condition that affects physical and mental development. The syndrome, also known as MCT8 deficiency, previously left families with few options, as the commercial cost for the drug in the United States could reach nearly Rs 9 crore without insurance.

For families like that of Surendra Kumar, a mechanical engineer in Hyderabad, the diagnosis was initially devastating. After his infant son showed signs of developmental delays, MRI scans revealed mild demyelination, and subsequent genetic testing confirmed AHDS. With an annual income of Rs 5.5 lakh, the prospect of a medication costing Rs 10 lakh per month was impossible. Dr. Sivaranjani identified six other children with the same condition, including five patients at Christian Medical College, Vellore. Recognizing that previous attempts to source the drug on compassionate grounds had failed, she launched a public awareness campaign in September 2025, tagging government officials and engaging the media.

How Hyderabad developed a path to treatment

The initiative gained momentum when the Pharmaceutical Accountability Foundation (PAF) in the Netherlands took interest in the case. While the pharmaceutical company Egetis Therapeutics AB holds a patent for the branded drug Emcitate, the patent does not cover the active ingredient, tiratricol, which is an established thyroid hormone metabolite. This legal distinction allowed a pharmacy in the Netherlands to produce test batches of the medication using the non-patented raw material. Through collaboration with patient advocacy groups like the Organization for Rare Diseases India and Access to Medicines India, the cost of the treatment was reduced to approximately Rs 2.5 lakh per child annually.

A pediatrician reduced rare disease treatment costs from crores to lakhs through international collaboration.

Why it matters

This initiative provides a lifeline for Indian families who previously faced insurmountable financial barriers to treating AHDS. By leveraging international pharmaceutical regulations and patient advocacy, this effort demonstrates a viable pathway for sourcing orphan drugs, potentially impacting how rare diseases are managed across South Asia.

Add NexVani Media as a preferred source on Google

Sources

ND

NexVani Desk

NexVani Media brings you the most important world news as it happens, with every story linked to its sources.